Oncolytics: A Failing Biopharma, Or An Opportune Buy? [View article]
MANY catalysts right now within a year or so! This is going to be up and down and up and.....agree on accumulation and trading a bit around a core position.
Anyhow, you notice that there are proteins downstream from p53 (Bax, Bak, etc.). Any mutation there and the p53 recovery becomes meaningless. Cancer cells typically have MANY mutations in various control elements and the cancer stem cells mutate fast. Cancer frequently becomes resistant to a certain treatment. There are some other posts pointing this out.
Volatile/well-shorted solar stocks are ripping higher (TAN +5.4%) to close out a week in which the EU imposed long-expected tariffs on Chinese solar panel imports. TSL +10%. CSIQ +16.1%. STP +9.1%. SCTY +8.6%. SOL +8.3%. JASO +7.5%. FSLR +4.6%. JKS +9.4%. LDK +3.4%. SPWR +7.8% A Reuters column today notes the pace of module price declines is expected to slow, as weaker players are forced out and U.S./emerging markets demand gradually soaks up excess capacity. [View news story]
Volatile/well-shorted solar stocks are ripping higher (TAN +5.4%) to close out a week in which the EU imposed long-expected tariffs on Chinese solar panel imports. TSL +10%. CSIQ +16.1%. STP +9.1%. SCTY +8.6%. SOL +8.3%. JASO +7.5%. FSLR +4.6%. JKS +9.4%. LDK +3.4%. SPWR +7.8% A Reuters column today notes the pace of module price declines is expected to slow, as weaker players are forced out and U.S./emerging markets demand gradually soaks up excess capacity. [View news story]
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
Please keep stop pulling stuff of the companies website to make an argument. Do you not see that its biased?
Anyhow: cancer is extremely complex. I agree the p53 adds to the picture in 50% of the cases, but it is NOT the sole item that needs to be restored typically. There are frequently multiple defects in the apoptosis pathway and p53 is pretty far upstream. So its naive to assume that you switch it back on it will work in these 50% of all cancers. It will help in some and that alone is great news. But this hype is really overdone. Here have a look where p53 sits and than start looking at other mutations downstream from there:
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
Well, nice hyping up there. In reality there are many companies with quite targeted drugs that are well tolerated. While I agree that this drug is excellent, I think it is one of many options. Look into ECYT to see another most excellent company in this area (long) or how about ONCY (selective virus).
I have published >100 papers too in various peer-reviewed journals. Not Nature or Science though but PNAS etc. Consultants are by definition a tad optimistic ;P
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
Question: why is this ueber-company traded OTC? A little weird to me. Also: cell culture experiments are nice but a pretty bad predictor of efficient medicine. I give you that big pharma argument though but this is way early.
Bill, why writing a complete article just to come to a mere technical conclusion? In addition, you will be wrong on the "pull back". I am not selling my LEAP calls.
Oncolytics: A Failing Biopharma, Or An Opportune Buy? [View article]
Jamie Dimon is threatening to leave JPMorgan (JPM) if stripped of the Chairman role, sources say. [View news story]
Enerplus' CEO Presents at Annual General Meeting Conference (Transcript) [View article]
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
http://bit.ly/11tm8ag
Anyhow, you notice that there are proteins downstream from p53 (Bax, Bak, etc.). Any mutation there and the p53 recovery becomes meaningless. Cancer cells typically have MANY mutations in various control elements and the cancer stem cells mutate fast. Cancer frequently becomes resistant to a certain treatment. There are some other posts pointing this out.
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
Volatile/well-shorted solar stocks are ripping higher (TAN +5.4%) to close out a week in which the EU imposed long-expected tariffs on Chinese solar panel imports. TSL +10%. CSIQ +16.1%. STP +9.1%. SCTY +8.6%. SOL +8.3%. JASO +7.5%. FSLR +4.6%. JKS +9.4%. LDK +3.4%. SPWR +7.8% A Reuters column today notes the pace of module price declines is expected to slow, as weaker players are forced out and U.S./emerging markets demand gradually soaks up excess capacity. [View news story]
Volatile/well-shorted solar stocks are ripping higher (TAN +5.4%) to close out a week in which the EU imposed long-expected tariffs on Chinese solar panel imports. TSL +10%. CSIQ +16.1%. STP +9.1%. SCTY +8.6%. SOL +8.3%. JASO +7.5%. FSLR +4.6%. JKS +9.4%. LDK +3.4%. SPWR +7.8% A Reuters column today notes the pace of module price declines is expected to slow, as weaker players are forced out and U.S./emerging markets demand gradually soaks up excess capacity. [View news story]
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
Anyhow: cancer is extremely complex. I agree the p53 adds to the picture in 50% of the cases, but it is NOT the sole item that needs to be restored typically. There are frequently multiple defects in the apoptosis pathway and p53 is pretty far upstream. So its naive to assume that you switch it back on it will work in these 50% of all cancers. It will help in some and that alone is great news. But this hype is really overdone. Here have a look where p53 sits and than start looking at other mutations downstream from there:
http://bit.ly/12iNr3J
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
I have published >100 papers too in various peer-reviewed journals. Not Nature or Science though but PNAS etc. Consultants are by definition a tad optimistic ;P
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
Apple: Too Far, Too Fast? [View article]
Apple: Too Far, Too Fast? [View article]
Apple: Too Far, Too Fast? [View article]